{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:01:25Z","timestamp":1790676085895,"version":"4.1.0"},"reference-count":44,"publisher":"The Endocrine Society","issue":"4","license":[{"start":{"date-parts":[[2019,12,14]],"date-time":"2019-12-14T00:00:00Z","timestamp":1576281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>The effect of sotagliflozin (a dual sodium\u2013glucose cotransporter [SGLT] 2 and SGLT1 inhibitor) on intestinal glucose absorption has not been investigated in humans.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To measure rate of appearance of oral glucose (RaO) using a dual glucose tracer method following standardized mixed meals taken after single sotagliflozin or canagliflozin doses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Clinical research organization<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design and participants<\/jats:title>\n                    <jats:p>In a double-blind, 3-period crossover study (NCT01916863), 24 healthy participants were randomized to 2 cohorts of 12 participants. Within each cohort, participants were randomly assigned single oral doses of either sotagliflozin 400 mg, canagliflozin 300 mg, or placebo on each of test days 1, 8, and 15. On test days, Cohort 1 had breakfast containing [6,6-2H2] glucose 0.25 hours postdose and lunch containing [1-2H1] glucose 5.25 hours postdose; Cohort 2 had breakfast containing no labeled glucose 0.25 hours postdose and lunch containing [6,6-2H2] glucose 4.25 hours postdose. All participants received a 10- to 15-hour continuous [U-13C6] glucose infusion starting 5 hours before their first [6,6-2H2] glucose-containing meal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcome<\/jats:title>\n                    <jats:p>RaO, postprandial glucose (PPG), and postprandial insulin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sotagliflozin and canagliflozin decreased area under the curve (AUC)0\u20131 hour and\/or AUC0\u20132 hours for RaO, PPG, and insulin after breakfast and\/or the 4.25-hour postdose lunch (P\u2005&amp;lt;\u2005.05 versus placebo). After the 5.25-hour postdose lunch, sotagliflozin lowered RaO AUC0\u20131 hour and PPG AUC0\u20135 hours versus both placebo and canagliflozin (P\u2005&amp;lt;\u2005.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Sotagliflozin delayed and blunted intestinal glucose absorption after meals, resulting in lower PPG and insulin levels, likely due to prolonged local inhibition of intestinal SGLT1 that persisted for \u22655 hours after dosing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgz258","type":"journal-article","created":{"date-parts":[[2019,12,14]],"date-time":"2019-12-14T11:27:20Z","timestamp":1576322840000},"page":"e1235-e1249","source":"Crossref","is-referenced-by-count":56,"title":["Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption"],"prefix":"10.1210","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0656-0124","authenticated-orcid":false,"given":"David R","family":"Powell","sequence":"first","affiliation":[{"name":"Lexicon Pharmaceuticals, Inc, The Woodlands, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Zambrowicz","sequence":"additional","affiliation":[{"name":"Lexicon Pharmaceuticals, Inc, The Woodlands, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Morrow","sequence":"additional","affiliation":[{"name":"ProSciento, Inc, Chula Vista, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Beysen","sequence":"additional","affiliation":[{"name":"ProSciento, Inc, Chula Vista, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Hompesch","sequence":"additional","affiliation":[{"name":"ProSciento, Inc, Chula Vista, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Turner","sequence":"additional","affiliation":[{"name":"Pliant Therapeutics, South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Hellerstein","sequence":"additional","affiliation":[{"name":"University of California, Berkeley, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Banks","sequence":"additional","affiliation":[{"name":"Lexicon Pharmaceuticals, Inc, The Woodlands, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Strumph","sequence":"additional","affiliation":[{"name":"Lexicon Pharmaceuticals, Inc, The Woodlands, Texas"},{"name":"Metavant Sciences, Ltd., Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Lapuerta","sequence":"additional","affiliation":[{"name":"Lexicon Pharmaceuticals, Inc, The Woodlands, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2019,12,14]]},"reference":[{"issue":"6","key":"2021122210034826800_CIT0001","doi-asserted-by":"crossref","first-page":"e12058","DOI":"10.14814\/phy2.12058","article-title":"SGLT2 inhibitors act from the extracellular surface of the cell membrane","volume":"2","author":"Ghezzi","year":"2014","journal-title":"Physiol Rep"},{"issue":"2","key":"2021122210034826800_CIT0002","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of human sodium glucose transporters","volume":"91","author":"Wright","year":"2011","journal-title":"Physiol Rev."},{"issue":"12","key":"2021122210034826800_CIT0003","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.2337\/dc15-0642","article-title":"Sodium-glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside","volume":"38","author":"Mudaliar","year":"2015","journal-title":"Diabetes Care."},{"issue":"4","key":"2021122210034826800_CIT0004","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/07853890.2011.560181","article-title":"A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials","volume":"44","author":"Musso","year":"2012","journal-title":"Ann Med."},{"issue":"7","key":"2021122210034826800_CIT0005","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med."},{"issue":"22","key":"2021122210034826800_CIT0006","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med."},{"issue":"9","key":"2021122210034826800_CIT0007","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","article-title":"Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials","volume":"6","author":"Perkovic","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"4","key":"2021122210034826800_CIT0008","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in Type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med."},{"issue":"9","key":"2021122210034826800_CIT0009","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.2337\/dc18-0343","article-title":"Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the North American inTandem1 Study","volume":"41","author":"Buse","year":"2018","journal-title":"Diabetes Care."},{"issue":"12","key":"2021122210034826800_CIT0010","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.2337\/dc18-1087","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study","volume":"41","author":"Dandona","year":"2018","journal-title":"Diabetes Care."},{"issue":"S2","key":"2021122210034826800_CIT0011","doi-asserted-by":"crossref","first-page":"S269","DOI":"10.1089\/dia.2018.0081","article-title":"Combined SGLT1 and SGLT2 inhibitors and their role in diabetes care","volume":"20","author":"Danne","year":"2018","journal-title":"Diabetes Technol Ther."},{"issue":"9","key":"2021122210034826800_CIT0012","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.2337\/dc18-0342","article-title":"HbA1c and hypoglycemia reductions at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: the European inTandem2 study","volume":"41","author":"Danne","year":"2018","journal-title":"Diabetes Care."},{"issue":"24","key":"2021122210034826800_CIT0013","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa1708337","article-title":"Effects of sotagliflozin added to insulin in patients with type 1 diabetes","volume":"377","author":"Garg","year":"2017","journal-title":"N Engl J Med."},{"issue":"10","key":"2021122210034826800_CIT0014","first-page":"967","article-title":"Effects of sotagliflozin added to insulin in type 1 diabetes","volume":"378","author":"Garg","year":"2018","journal-title":"N Engl J Med."},{"issue":"9","key":"2021122210034826800_CIT0015","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.2337\/dc18-0623","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 Study): 24-week results from a randomized controlled trial","volume":"41","author":"Mathieu","year":"2018","journal-title":"Diabetes Care."},{"issue":"12","key":"2021122210034826800_CIT0016","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.2337\/dc18-1749","article-title":"Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials","volume":"41","author":"Rosenstock","year":"2018","journal-title":"Diabetes Care."},{"issue":"5","key":"2021122210034826800_CIT0017","doi-asserted-by":"crossref","first-page":"919","DOI":"10.2337\/dc18-2149","article-title":"Improved time in range and glycemic variability with sotagliflozin in combination with insulin in adults with type 1 diabetes: a pooled analysis of 24-week continuous glucose monitoring data from the inTandem program","volume":"42","author":"Danne","year":"2019","journal-title":"Diabetes Care."},{"issue":"2","key":"2021122210034826800_CIT0018","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/clpt.2012.58","article-title":"LX4211, a dual SGLT1\/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial","volume":"92","author":"Zambrowicz","year":"2012","journal-title":"Clin Pharmacol Ther."},{"issue":"7","key":"2021122210034826800_CIT0019","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.2337\/dc14-2806","article-title":"Sotagliflozin, a Dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes","volume":"38","author":"Sands","year":"2015","journal-title":"Diabetes Care."},{"issue":"2","key":"2021122210034826800_CIT0020","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1124\/jpet.114.214304","article-title":"Effect of LX4211 on glucose homeostasis and body composition in preclinical models","volume":"350","author":"Powell","year":"2014","journal-title":"J Pharmacol Exp Ther."},{"issue":"2","key":"2021122210034826800_CIT0021","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1124\/jpet.113.203364","article-title":"LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium\/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose","volume":"345","author":"Powell","year":"2013","journal-title":"J Pharmacol Exp Ther."},{"issue":"3","key":"2021122210034826800_CIT0022","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.clinthera.2013.01.010","article-title":"Effects of LX4211, a dual SGLT1\/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes","volume":"35","author":"Zambrowicz","year":"2013","journal-title":"Clin Ther."},{"issue":"8","key":"2021122210034826800_CIT0023","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.2337\/dc12-2391","article-title":"Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study","volume":"36","author":"Polidori","year":"2013","journal-title":"Diabetes Care."},{"issue":"7","key":"2021122210034826800_CIT0024","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1463-1326.2011.01406.x","article-title":"Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects","volume":"13","author":"Sha","year":"2011","journal-title":"Diabetes Obes Metab."},{"issue":"2","key":"2021122210034826800_CIT0025","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/dom.12418","article-title":"Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study","volume":"17","author":"Sha","year":"2015","journal-title":"Diabetes Obes Metab."},{"issue":"10","key":"2021122210034826800_CIT0026","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.metabol.2014.07.003","article-title":"Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial","volume":"63","author":"Stein","year":"2014","journal-title":"Metabolism."},{"issue":"7","key":"2021122210034826800_CIT0027","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2337\/diab.17.7.415","article-title":"Glucose uptake and production during the oral glucose tolerance test","volume":"17","author":"Steele","year":"1968","journal-title":"Diabetes."},{"issue":"11","key":"2021122210034826800_CIT0028","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1111\/dom.13825","article-title":"Dose-dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12\u2009weeks: the inTandem4 trial","volume":"21","author":"Baker","year":"2019","journal-title":"Diabetes Obes Metab."},{"issue":"3","key":"2021122210034826800_CIT0029","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.diabres.2014.03.012","article-title":"Residual dysglycemia when at target HbA(1c) of 7% (53mmol\/mol) in persons with type 2 diabetes","volume":"104","author":"Monnier","year":"2014","journal-title":"Diabetes Res Clin Pract."},{"issue":"1","key":"2021122210034826800_CIT0030","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11154-016-9325-8","article-title":"Near normal HbA1c with stable glucose homeostasis: the ultimate target\/aim of diabetes therapy","volume":"17","author":"Monnier","year":"2016","journal-title":"Rev Endocr Metab Disord."},{"issue":"2","key":"2021122210034826800_CIT0031","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2337\/cd17-0094","article-title":"Does time-in-range matter? Perspectives from people with diabetes on the success of current therapies and the drivers of improved outcomes","volume":"36","author":"Runge","year":"2018","journal-title":"Clin Diabetes."},{"issue":"3","key":"2021122210034826800_CIT0032","doi-asserted-by":"crossref","first-page":"400","DOI":"10.2337\/dc18-1444","article-title":"Validation of time in range as an outcome measure for diabetes clinical trials","volume":"42","author":"Beck","year":"2019","journal-title":"Diabetes Care."},{"issue":"11","key":"2021122210034826800_CIT0033","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.2337\/dc18-1131","article-title":"Association of time in range, as assessed by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes","volume":"41","author":"Lu","year":"2018","journal-title":"Diabetes Care."},{"issue":"5","key":"2021122210034826800_CIT0034","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00125-014-3196-x","article-title":"Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes","volume":"57","author":"Polidori","year":"2014","journal-title":"Diabetologia."},{"issue":"15","key":"2021122210034826800_CIT0035","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.jacc.2018.07.061","article-title":"Genetic variants in SGLT1, glucose tolerance, and cardiometabolic risk","volume":"72","author":"Seidelmann","year":"2018","journal-title":"J Am Coll Cardiol."},{"issue":"11","key":"2021122210034826800_CIT0036","doi-asserted-by":"crossref","first-page":"G946","DOI":"10.1152\/ajpgi.00286.2014","article-title":"Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release","volume":"308","author":"Dobbins","year":"2015","journal-title":"Am J Physiol Gastrointest Liver Physiol."},{"issue":"2","key":"2021122210034826800_CIT0037","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1021\/acs.jmedchem.6b01541","article-title":"Discovery of LX2761, a sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor restricted to the intestinal lumen, for the treatment of diabetes","volume":"60","author":"Goodwin","year":"2017","journal-title":"J Med Chem."},{"issue":"1","key":"2021122210034826800_CIT0038","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1124\/jpet.117.240820","article-title":"LX2761, a sodium\/glucose cotransporter 1 inhibitor restricted to the intestine, improves glycemic control in mice","volume":"362","author":"Powell","year":"2017","journal-title":"J Pharmacol Exp Ther."},{"issue":"2","key":"2021122210034826800_CIT0039","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1124\/jpet.112.193045","article-title":"KGA-2727, a novel selective inhibitor of a high-affinity sodium glucose cotransporter (SGLT1), exhibits antidiabetic efficacy in rodent models","volume":"342","author":"Shibazaki","year":"2012","journal-title":"J Pharmacol Exp Ther."},{"issue":"2","key":"2021122210034826800_CIT0040","doi-asserted-by":"crossref","first-page":"E117","DOI":"10.1152\/ajpendo.00439.2012","article-title":"Improved glycemic control in mice lacking Sglt1 and Sglt2","volume":"304","author":"Powell","year":"2013","journal-title":"Am J Physiol Endocrinol Metab."},{"issue":"2","key":"2021122210034826800_CIT0041","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","volume":"124","author":"Merovci","year":"2014","journal-title":"J Clin Invest."},{"issue":"2","key":"2021122210034826800_CIT0042","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J Clin Invest."},{"issue":"6","key":"2021122210034826800_CIT0043","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.2337\/db17-1278","article-title":"Endogenous glucose production and hormonal changes in response to canagliflozin and liraglutide combination therapy","volume":"67","author":"Martinez","year":"2018","journal-title":"Diabetes."},{"key":"2021122210034826800_CIT0044","author":"Center for Drug Evaluation and Research, U.S. Food and Drug Administration","year":"2019"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgz258\/31518203\/dgz258.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/4\/e1235\/41863133\/jcem_105_4_e1235.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/4\/e1235\/41863133\/jcem_105_4_e1235.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T13:12:53Z","timestamp":1640178773000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/105\/4\/e1235\/5677527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,14]]},"references-count":44,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,12,14]]},"published-print":{"date-parts":[[2020,4,1]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgz258","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,4]]},"published":{"date-parts":[[2019,12,14]]}}}